Clinical trials: Dyslipidaemia
Diabetes Mellitus, Type 2, Insulin Resistance
Production of Free Fatty Acids From Blood Triglycerides
The overall hypothesis of these studies is that circulating triglycerides, coming primarily from fat in the diet, are an important source of free fatty acids.
- Conditions
- Diabetes Mellitus, Type 2, Insulin Resistance, Dyslipidemias
- Trial name
- NCT00911482
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Cardiovascular Diseases, Hypercholesterolemia
Plant Sterols on Cardiovascular Markers, Microbiota and Sterol Metabolism (Cardiofoodsterol)
Potential cholesterol-lowering effect of a regular intake of a plant sterol (PS)-containing food supplement, in overweight/obese type 1 or 2, normoglycemic/pre-diabetic, with LDL-cholesterol values > 115 mg/dl and not…
- Conditions
- Cardiovascular Diseases, Hypercholesterolemia, Prediabetic State, Overweight and Obesity
- Trial name
- NCT06481020
- Testing
- Plant sterols 2g/day
- Where
- Spain
- Volunteers
- 42 people
- Sponsor
- University of Valencia
Complex Dyslipidemia
A Observational Study to Evaluate Lipid-lowering Drug Its Effect on Parameters in Dyslipidemia of Type 2 Diabetes.
1. Target disease: Patients with combined dyslipidemia accompanied by type 2 diabetes who has done exogenous visit or hospitalization from Jan 2010 to June 2014. 2. Study objective: 1.
- Trial name
- NCT02382159
- Where
- South Korea
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Yooyoung Pharmaceutical Co., Ltd.
Diabetes Mellitus
Efficacy and Safety of Alogliptin Combined With Metformin in Participants With Type 2 Diabetes Mellitus
The purpose of this study is to evaluate the efficacy and safety of alogliptin, once daily (QD), combined with metformin in adults with type 2 diabetes mellitus.
- Trial name
- NCT00286442
- Testing
- Alogliptin and metformin, Metformin
- Where
- 56 sites in United States, Argentina and 15 more
- Volunteers
- 527 people
- Sponsor
- Takeda
Elevated LDL-C and High Cholesterol
A Study of STX-1150 in Participants With Elevated Low-Density Lipoprotein Cholesterol (LDL-C)
STX-1150 is an investigational therapy designed to lower LDL-C by silencing a gene called PCSK9 in the liver. STX-1150 does not edit or permanently change the gene.
- Trial name
- STX-1150-01 (NCT07428473)
- Testing
- STX-1150
- Where
- 3 sites in Australia, New Zealand
- Volunteers
- 64 people
- Sponsor
- Monash University
Cardiometabolic Syndrome, Dyslipidemias
Efficacy of Tamarindus Indica Fruit Juice in Optimizing Cardiometabolic Health of Patients Living With HIV
The increasing burden of metabolic disturbances among People Living with HIV especially in developing countries has posed need for scientifically-proven, innovative, sustainable and cost-effective local adjuvant remedies to…
- Conditions
- Cardiometabolic Syndrome, Dyslipidemias, Hypertension
- Trial name
- NCT06058845
- Testing
- Tamarindus indica fruit juice_A, Tamarindus indica fruit juice_B
- Where
- Uganda
- Volunteers
- 50 people
- Sponsor
- KU Leuven
Metabolic Syndrome
Assessment of Therapeutic Potential of Stigma Maydis (Cornsilk) on Metabolic Syndrome
Over the past two decades, there has been an increase in the number of people with nutrition related maladies due to changes in their dietary habits and lifestyle.
- Trial name
- cornsilk (NCT06240273)
- Testing
- Corn silk powder
- Volunteers
- 50 people
- Sponsor
- University of Veterinary and Animal Sciences, Lahore - Pakistan
Hypercholesterolemia, Hyperlipoproteinemia
A Study Comparing the Mechanisms of Action of Lifibrol and Pravastatin
Lifibrol is a new lipid-lowering drug which lowers cholesterol to an extent in the order of magnitude of the statins. The mechanism of action of this compound is different from the one of statins but remains unknown.
- Trial name
- NCT01057654
- Testing
- Pravastatin, Lifibrol
- Where
- Germany
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- University Hospital, Bonn
Lipoprotein Disorder
A Study of LY3473329 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events
The main purpose of this study is to evaluate the efficacy and safety of LY3473329 in adult participants with elevated Lp(a) at high risk for cardiovascular events.
- Trial name
- KRAKEN (NCT05563246)
- Testing
- LY3473329
- Where
- 42 sites in United States, Australia and 6 more
- Volunteers
- 233 people
- Sponsor
- Eli Lilly and Company
Dyslipidemia, Diabetes
Meta-analyses of the Effect of Important Food Sources of Sugars on Cardiometabolic Risk Factors
Fructose-containing sugars have been implicated in the epidemics of obesity, diabetes and related cardiometabolic disorders. This view is supported by lower quality evidence from ecological observations, animal models, and select…
- Conditions
- Dyslipidemia, Diabetes, Prediabetes, Dysglycemia
- Trial name
- NCT02716870
- Testing
- Fructose-containing Sugars
- Where
- Canada
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- University of Toronto
Hyperlipidemia, Type 2 Diabetes
A Single Center Study to Evaluate the Efficacy and Safety of ETC 1002 in Subjects With Type 2 Diabetes
This Phase 2 study will asses the LDL-C lowering efficacy of ETC-1002 versus placebo in subjects with type 2 diabetes.
- Trial name
- NCT01607294
- Testing
- ETC-1002
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Esperion Therapeutics, Inc.
Hypertension, Dyslipidemia
Evaluation of the Effectiveness and Safety of Rozetel Tablet in Patients After PCI: A Multi-Center Observational Study
The purpose of this study is to evaluate the effectiveness and safety of the investigational drug on blood pressure and LDL cholesterol control during the observation period in patients who have undergone percutaneous coronary…
- Trial name
- NCT07084246
- Where
- South Korea
- Volunteers
- 1,563 people
- Sponsor
- GC Biopharma Corp
Obesity, Overweight
Pediatric Preventative Health Screenings - Obesity and Family-Centered Outcomes
In 2012, an Expert Panel of the National Heart Lung and Blood Institute published guidelines on cardiovascular health and risk reduction in children; among these guidelines were screening recommendations for obesity and…
- Conditions
- Obesity, Overweight, Blood Pressure, Hypercholesteremia
- Trial name
- NCT02850224
- Testing
- Motivational interviewing to elicit PCO in pediatrics
- Where
- United States
- Volunteers
- 703 people, healthy volunteers welcome
- Sponsor
- Henry Ford Health System
Dyslipidemias, Non-Alcoholic Fatty Liver Disease
A Study of LY3885125 in Participants With Dyslipidemia or Non-Alcoholic Fatty Liver Disease (NAFLD)
The main purpose of this study is to evaluate the safety and tolerability of LY3885125 after administration of single ascending doses in participants with dyslipidemia (part A) and multiple doses in participants with…
- Trial name
- NCT06007651
- Testing
- LY3885125
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- Eli Lilly and Company
Cardiac Disease, Cancer
Electronic Medical Records and Genomics (eMERGE) Phase III
The Electronic Medical Records and Genomics (eMERGE) Network is in its third phase and during this time is enrolling and sequencing 25,000 individuals on a custom sequencing panel of clinically relevant, actionable genes.
- Conditions
- Cardiac Disease, Cancer, Hypercholesterolemia, Diabetes
- Trial name
- eMERGE (NCT03394859)
- Volunteers
- 25,380 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University Medical Center
Hypercholesterolemia
Evaluation of Safety and Efficacy of AVE5530 as add-on to Ongoing High Doses of Statins in Patients With Primary Severe Hypercholesterolemia
The present study is assessing the efficacy and safety of AVE5530 (25 mg and 50 mg) in add-on to ongoing treatment with high doses of statin in a double-blind manner in comparison with placebo, in the management of patients with…
- Trial name
- NCT00766688
- Testing
- AVE5530
- Where
- 13 sites in United States, Australia and 11 more
- Volunteers
- 643 people
- Sponsor
- Sanofi
Lipid Metabolism, Inborn Errors, Hypercholesterolemia, Autosomal Dominant
Study to Assess the Safety and Efficacy of ISIS 301012 (Mipomersen) in Homozygous Familial Hypercholesterolemia
The purpose of this study is to evaluate the safety and efficacy of mipomersen (ISIS 301012) in subjects with homozygous familial hypercholesterolemia on lipid-lowering therapy.
- Conditions
- Lipid Metabolism, Inborn Errors, Hypercholesterolemia, Autosomal Dominant, Hyperlipidemias, Metabolic Diseases
- Trial name
- RADICHOL 1 (NCT00607373)
- Testing
- mipomersen
- Where
- 10 sites in United States, Brazil and 5 more
- Volunteers
- 51 people
- Sponsor
- Kastle Therapeutics, LLC
Coronary Artery Disease, Hypercholesterolemia
A Trial Assessing the Effectiveness of Evolocumab in Reducing the Plaque Burden in Participants With Subclinical Atheroma
The main aim of this trial is to demonstrate that Evolocumab plus routine lipid management is superior to routine lipid management alone in modifying plaque (non-calcified) volume as measured by Artificial Intelligence-enabled…
- Conditions
- Coronary Artery Disease, Hypercholesterolemia, Atheroma, Atherosclerotic Plaque
- Trial name
- NCT07803679
- Testing
- Evolocumab, Routine Lipid Management, Autoinjector
- Volunteers
- 308 people
- Sponsor
- Amgen
Hypercholesterolemia
Tolerability and Lipid Lowering Effect of Weekly/Biweekly Crestor in Statin Intolerant Patients Treated With Zetia
Recently, research studies have shown that patients who have had trouble taking statins every day, are able to take statins if they take them only once or twice a week.
- Trial name
- NCT00972829
- Testing
- Rosuvastatin, Ezetimibe
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Bronx VA Medical Center
Dyslipidemias
Phase 1 to Evaluate the Safety and Pharmacokinetic Characteristics of Fixed-dose Combination of YYC506
To evaluate the safety and pharmacokinetics characteristics between YYC506 and concomitant administration of YYC506-T and YYC506-A
- Trial name
- NCT04874129
- Testing
- YYC506-T and YYC506-A (phase 1), YYC506 (phase 1), YYC506-T and YYC506-A (phase 2)
- Where
- South Korea
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Yooyoung Pharmaceutical Co., Ltd.